Biological Rationale for Radiation-induced Release of Circulating Tumor DNA

Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer

Colorectal cancer (CRC) has been the fourth leading cause of cancer-related mortality worldwide. Owing to clonal evolution and selection, CRC treatment needs multimodal therapeutic approaches and due monitoring of tumor progression and therapeutic efficacy. Liquid biopsy, involving the use of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes, may offer a promising noni...

Circulating tumor DNA--ready for prime time?

Multiple aspects of the management of metastatic breast cancer need improvement. Patients are anxious about their risk of recurrence and are disappointed at the lack of reliable tests for the early detection of recurrence, even though there are no data to suggest that detection of asymptomatic recurrences a few weeks or months earlier is of any benefit. It seems reasonable that identifying resi...

Circulating Tumor DNA Testing for Liver Cancer

irculating tumor DNA (ctDNA) analysis represents a Cpotential paradigm shift in personalized medicine. Unlike tissue biopsy, it constitutes a minimally invasive approach that allows for diagnostic, predictive, and prognostic marker detection, early and serial assessment of metastatic disease, therapy monitoring, and determination of clonal evolution. Because ctDNA reflects genetic and epigeneti...

Fragment Length of Circulating Tumor DNA

Malignant tumors shed DNA into the circulation. The transient half-life of circulating tumor DNA (ctDNA) may afford the opportunity to diagnose, monitor recurrence, and evaluate response to therapy solely through a non-invasive blood draw. However, detecting ctDNA against the normally occurring background of cell-free DNA derived from healthy cells has proven challenging, particularly in non-me...

Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy)